Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
New drugs from Eli Lilly have produced a strong showing in the first quarter, in what could be a key year for a company still recovering from patent expiry of its former blockbuster antidep
